Related Experiment Video

Updated: May 7, 2026

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
07:49

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model

Published on: April 13, 2015

Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy

Sherene Loi1

  • 1Translational Breast Cancer Genomics Lab; Cancer Therapeutics Program; Peter MacCallum Cancer Centre; St. Andrews Place; East Melbourne, VIC Australia ; Sir Peter MacCallum Department of Oncology; University of Melbourne; Parkville, VIC Australia.

Oncoimmunology
|September 28, 2013
PubMed

By analyzing over 2000 samples from a randomized clinical trial, we have recently associated high levels of tumor-infiltrating lymphocytes with an excellent prognosis among triple negative breast cancer patients as well with improved clinical responses to immunogenic chemotherapy among patients bearing HER2 over-expression. These findings suggest that immunomodulation could represent a new approach to treat these aggressive breast cancer subtypes.

Keywords:
biomarkersbreast cancerimmunotherapiesprognosistrastuzumab efficacytumor infiltrating lymphocytes

More Related Videos

Predictive Immune Modeling of Solid Tumors08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.